RNS Number: 0839A Convatec Group PLC 11 March 2025

11 March 2025

## Convatec Group Plc ("Convatec" or "the Company")

## Annual Report and Accounts 2024 and Notice of Annual General Meeting

The Company's annual general meeting (the "Annual General Meeting") will take place at 14:00 (UK time) on Thursday 22 May 2025 at FGS Global, The Adelphi, 1-11 John Adam Street, London WC2N 6HT.

The Company's Annual Report and Accounts for the year ended 31 December 2024 and the Notice of Annual General Meeting, including details of how shareholders can appoint a proxy, are being sent to shareholders today and have been submitted to the National Storage Mechanism in accordance with paragraph 17.2.1 of the FCA Listing Rules. A copy of the Convatec Group Omnibus Incentive Plan has also been submitted to the National Storage Mechanism. These documents will shortly be available for inspection at <a href="https://data.fca.org.uk/#/nsm/nationalstoragemechanism">https://data.fca.org.uk/#/nsm/nationalstoragemechanism</a>.

A copy of the Company's Annual Report and Accounts and the Notice of Annual General Meeting can be accessed on the Company's website at <a href="www.convatecgroup.com">www.convatecgroup.com</a>.

This announcement is made in accordance with DTR 6.3.5R(1A).

## **Enquiries**

James Kerton, Company Secretary

Tel: +44 (7827) 036059

Email: cosec@convatec.com

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 1.1 Annual financial and audit reports

## **About Convatec**

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over 2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:msc.decombox.ns.com">msc.decombox.ns.com</a>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <a href="Privacy Policy">Privacy Policy</a>.